Sensato Investors LLC reduced its stake in Astrazeneca PLC (NYSE:AZN) by 59.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 76,900 shares of the company’s stock after selling 114,600 shares during the period. Sensato Investors LLC’s holdings in Astrazeneca PLC were worth $2,395,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in AZN. Russell Investments Group Ltd. bought a new position in Astrazeneca PLC during the fourth quarter valued at approximately $2,014,000. Comerica Bank increased its position in Astrazeneca PLC by 9.9% in the fourth quarter. Comerica Bank now owns 165,727 shares of the company’s stock valued at $4,737,000 after buying an additional 14,884 shares during the period. Dimensional Fund Advisors LP increased its position in Astrazeneca PLC by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,046,081 shares of the company’s stock valued at $55,899,000 after buying an additional 44,002 shares during the period. Baird Financial Group Inc. increased its position in Astrazeneca PLC by 1.8% in the fourth quarter. Baird Financial Group Inc. now owns 52,656 shares of the company’s stock valued at $1,439,000 after buying an additional 919 shares during the period. Finally, Gabelli Funds LLC increased its position in Astrazeneca PLC by 3.7% in the fourth quarter. Gabelli Funds LLC now owns 197,000 shares of the company’s stock valued at $5,382,000 after buying an additional 7,000 shares during the period. 14.00% of the stock is currently owned by hedge funds and other institutional investors.
Astrazeneca PLC (NYSE AZN) traded up 0.23% on Tuesday, reaching $34.72. 5,164,356 shares of the company’s stock were exchanged. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.27. The firm has a 50 day moving average price of $33.40 and a 200 day moving average price of $30.06. The firm has a market cap of $87.91 billion, a PE ratio of 26.01 and a beta of 0.81.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, April 27th. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.61. The firm had revenue of $5.41 billion during the quarter, compared to the consensus estimate of $5.40 billion. Astrazeneca PLC had a return on equity of 35.65% and a net margin of 15.21%. The company’s quarterly revenue was down 11.6% on a year-over-year basis. During the same period last year, the company earned $0.95 EPS. On average, equities analysts anticipate that Astrazeneca PLC will post $1.86 earnings per share for the current year.
Several equities analysts have recently commented on AZN shares. Berenberg Bank reissued a “buy” rating on shares of Astrazeneca PLC in a report on Tuesday, February 21st. Vetr raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating and set a $30.84 target price on the stock in a report on Tuesday, February 21st. TheStreet raised shares of Astrazeneca PLC from a “c+” rating to a “b-” rating in a report on Tuesday, February 28th. Cowen and Company reissued a “market perform” rating on shares of Astrazeneca PLC in a report on Monday, March 6th. Finally, Barclays PLC started coverage on shares of Astrazeneca PLC in a report on Tuesday, March 7th. They issued an “overweight” rating on the stock. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. Astrazeneca PLC presently has a consensus rating of “Hold” and a consensus target price of $35.84.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.